Diabetic
Conditions
Interventions
After registration, patients are administered Ipragliflozin. (trade name: Sugura) If you do not achieve the blood glucose effect goal, patients can be used in combination with other drugs
Sponsors
Nagasaki University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Diagnostic criteria of diabetes (to comply with diabetes diagnostic criteria of Japan Diabetes Society) - Early morning fasting blood glucose level 126mg/over -75gOGTT (2-hour value)200mg/dl over - Random blood glucose level 200mg/dl over - HbA1c(NGSP)6.5%over
Exclusion criteria
Exclusion criteria: - Phlebotomy treatment patients - Patients with a history of heart failure patients and heart failure - Patients with a history of cerebral infarction - Patients with severe ketosis, diabetic coma or precoma, of type 1 diabetes - Patients with severe liver dysfunction (attending physician judgment) - Patients with severe renal dysfunction (dialysis example or GFR <10-30ml/min) - Severe infection, before and after surgery, patients with severe trauma - Patients with a history of hypersensitivity to components of this drug - Women that might be pregnant or pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AST,ALT,HbA1c,Fasting blood glucose or random blood glucose,IRI,BMI,Plt,TC,LDL-C,HDL-C,TG | — |
Secondary
| Measure | Time frame |
|---|---|
| AFP,PIVKA2,Hyaluronic acid (limited to patients with chronic hepatitis) | — |
Countries
Japan
Contacts
Public ContactKazuhiko Nakao
Nagasaki University Hospital Gastroenterology
Outcome results
None listed